Literature DB >> 20680408

Effects of ranolazine on fatty acid transformation in the isolated perfused rat liver.

Márcio Shigueaki Mito1, Jorgete Constantin, Cristiane Vizioli de Castro, Nair Seiko Yamamoto, Adelar Bracht.   

Abstract

It has been proposed that in the heart, ranolazine shifts the energy source from fatty acids to glucose oxidation by inhibiting fatty acid oxidation. Up to now no mechanism for this inhibition has been proposed. The purpose of this study was to investigate if ranolazine also affects hepatic fatty acid oxidation, with especial emphasis on cell membrane permeation based on the observations that the compound interacts with biological membranes. The isolated perfused rat liver was used, and [1-(14)C]oleate transport was measured by means of the multiple-indicator dilution technique. Ranolazine inhibited net uptake of [1-(14)C]-oleate by impairing transport of this fatty acid. The compound also diminished the extra oxygen consumption and ketogenesis driven by oleate and the mitochondrial NADH/NAD(+) ratio, but stimulated (14)CO(2) production. These effects were already significant at 20 μM ranolazine. Ranolazine also inhibited both oxygen consumption and ketogenesis driven by endogenous fatty acids in substrate-free perfused livers. In isolated mitochondria ranolazine inhibited acyl-CoA oxidation and β-hydroxybutyrate or α-ketoglutarate oxidation coupled to ADP phosphorylation. It was concluded that ranolazine inhibits fatty acid uptake and oxidation in the liver by at least two mechanisms: inhibition of cell membrane permeation and by an inhibition of the mitochondrial electron transfer via pyridine nucleotides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680408     DOI: 10.1007/s11010-010-0557-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  A simple and rapid assay of oxidative phosphorylation.

Authors:  B CHANCE; G R WILLIAMS
Journal:  Nature       Date:  1955-06-25       Impact factor: 49.962

3.  Mechanism of action of ranolazine.

Authors:  Celeste Marx; Michael Sweeney
Journal:  Arch Intern Med       Date:  2006-06-26

4.  A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.

Authors:  Peipei Wang; Heather Fraser; Steven G Lloyd; Jeffrey J McVeigh; Luiz Belardinelli; John C Chatham
Journal:  J Pharmacol Exp Ther       Date:  2007-01-03       Impact factor: 4.030

5.  Capillary exchange modeling. Barrier-limited and flow-limited distribution.

Authors:  C A Goresky; W H Ziegler; G G Bach
Journal:  Circ Res       Date:  1970-11       Impact factor: 17.367

6.  Effects of saturating metabolic uptake on space profiles and tracer kinetics.

Authors:  C A Goresky; G G Bach; C P Rose
Journal:  Am J Physiol       Date:  1983-02

Review 7.  Ranolazine. A metabolic modulator for the treatment of chronic stable angina.

Authors:  Joe R Anderson; James J Nawarskas
Journal:  Cardiol Rev       Date:  2005 Jul-Aug       Impact factor: 2.644

8.  FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts.

Authors:  Jürgen Pohl; Axel Ring; Umine Korkmaz; Robert Ehehalt; Wolfgang Stremmel
Journal:  Mol Biol Cell       Date:  2004-10-20       Impact factor: 4.138

9.  Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase.

Authors:  B Clarke; M Spedding; L Patmore; J G McCormack
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.

Authors:  J G McCormack; R L Barr; A A Wolff; G D Lopaschuk
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

View more
  3 in total

1.  Assessment and histological analysis of the IPRL technique for sequential in situ liver biopsy.

Authors:  Anthony Rowe; Lillian Zhang; Azmena Hussain; Filip Braet; Iqbal Ramzan
Journal:  Comp Hepatol       Date:  2011-08-08

2.  Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.

Authors:  Alexander C Fanaroff; Stefan K James; Giora Weisz; Kristi Prather; Kevin J Anstrom; Daniel B Mark; Ori Ben-Yehuda; Karen P Alexander; Gregg W Stone; E Magnus Ohman
Journal:  J Am Coll Cardiol       Date:  2017-05-09       Impact factor: 24.094

3.  Toluidine blue O directly and photodynamically impairs the bioenergetics of liver mitochondria: a potential mechanism of hepatotoxicity.

Authors:  Karina Borba Paulino Dos Santos; Ana Flavia Gatto Raimundo; Eduardo Makiyama Klosowski; Byanca Thais Lima de Souza; Márcio Shigueaki Mito; Renato Polimeni Constantin; Gislaine Cristiane Mantovanelli; Juliana Morais Mewes; Paulo Francisco Veiga Bizerra; Paulo Vinicius Moreira da Costa Menezes; Karina Sayuri Utsunomiya; Eduardo Hideo Gilglioni; Rogério Marchiosi; Wanderley Dantas Dos Santos; Osvaldo Ferrarese-Filho; Wilker Caetano; Paulo Cesar de Souza Pereira; Renato Sonchini Gonçalves; Jorgete Constantin; Emy Luiza Ishii-Iwamoto; Rodrigo Polimeni Constantin
Journal:  Photochem Photobiol Sci       Date:  2022-09-24       Impact factor: 4.328

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.